(CI) Cigna - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 77.053m USD | Total Return: -7.3% in 12m
Avg Turnover: 462M
EPS Trend: 95.7%
Qual. Beats: 1
Rev. Trend: 98.5%
Qual. Beats: 13
Warnings
Earnings expected to drop: P/E 2.6 → Forward 9.5
Below Avwap Earnings
Tailwinds
No distinct edge detected
The Cigna Group is a global health services organization operating primarily through two core segments: Evernorth Health Services and Cigna Healthcare. Evernorth focuses on pharmacy benefit management (PBM), specialty pharmacy distribution, and clinical care services. Cigna Healthcare provides medical insurance plans to employers, individuals, and government entities, alongside dental and behavioral health solutions.
The company utilizes a diversified distribution model, selling products through brokers, consultants, and direct-to-consumer channels. As a major player in the PBM sector, Cigna operates in a highly consolidated industry where three large entities manage approximately 80% of all prescription drug claims in the United States. This integrated business model allows the firm to capture margins across both the financing and delivery of healthcare services.
Investors can evaluate the company’s long-term valuation metrics and historical performance trends on ValueRay. Founded in 1792 and headquartered in Bloomfield, Connecticut, the company rebranded from Cigna Corporation to The Cigna Group in 2023 to reflect its expanded focus beyond traditional insurance.
- Evernorth pharmacy benefit management margins drive consolidated revenue growth and earnings
- Medical loss ratio fluctuations impact profitability within the Cigna Healthcare segment
- Federal pharmacy benefit manager transparency legislation poses significant regulatory and margin risk
- Specialty pharmacy growth and biosimilar adoption accelerate Evernorth Health Services expansion
- Aggressive share repurchase programs and dividend increases support long term shareholder value
| Net Income: 6.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.01 > 1.0 |
| NWC/Revenue: -3.44% < 20% (prev -4.77%; Δ 1.33% < -1%) |
| CFO/TA 0.06 > 3% & CFO 8.81b > Net Income 6.29b |
| Net Debt (23.1b) to EBITDA (11.9b): 1.94 < 3 |
| Current Ratio: 0.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (264.2m) vs 12m ago -6.71% < -2% |
| Gross Margin: 9.30% > 18% (prev 0.10%; Δ 919.8% > 0.5%) |
| Asset Turnover: 182.9% > 50% (prev 169.5%; Δ 13.40% > 0%) |
| Interest Coverage Ratio: 6.77 > 6 (EBITDA TTM 11.9b / Interest Expense TTM 1.38b) |
| A: -0.06 (Total Current Assets 43.0b - Total Current Liabilities 52.6b) / Total Assets 153b |
| B: 0.32 (Retained Earnings 49.1b / Total Assets 153b) |
| C: 0.06 (EBIT TTM 9.32b / Avg Total Assets 152b) |
| D: 0.41 (Book Value of Equity 45.5b / Total Liabilities 111b) |
| Altman-Z'' = 1.48 = BB |
| DSRI: 0.93 (Receivables 26.6b/26.2b, Revenue 278b/255b) |
| GMI: 1.10 (GM 9.30% / 10.25%) |
| AQI: 1.01 (AQ_t 0.70 / AQ_t-1 0.69) |
| SGI: 1.09 (Revenue 278b / 255b) |
| TATA: -0.02 (NI 6.29b - CFO 8.81b) / TA 153b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of May 25, 2026, the stock is trading at USD 282.02 with a total of 854,653 shares traded.
Over the past week, the price has changed by +0.34%,
over one month by +3.85%,
over three months by +2.43% and
over the past year by -7.29%.
Cigna has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy CI.
- StrongBuy: 13
- Buy: 6
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 340.5 | 20.7% |
P/E Forward = 9.4877
P/S = 0.2773
P/B = 1.8053
P/EG = 0.8623
Revenue TTM = 278b USD
EBIT TTM = 9.32b USD
EBITDA TTM = 11.9b USD
Long Term Debt = 29.4b USD (from longTermDebt, last quarter)
Short Term Debt = 1.53b USD (from shortTermDebt, last quarter)
Debt = 31.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 87.0m
Net Debt = 23.1b USD (calculated: Debt 31.0b - CCE 7.85b)
Enterprise Value = 100b USD (77.1b + Debt 31.0b - CCE 7.85b)
Interest Coverage Ratio = 6.77 (Ebit TTM 9.32b / Interest Expense TTM 1.38b)
EV/FCF = 13.08x (Enterprise Value 100b / FCF TTM 7.66b)
FCF Yield = 7.65% (FCF TTM 7.66b / Enterprise Value 100b)
FCF Margin = 2.76% (FCF TTM 7.66b / Revenue TTM 278b)
Net Margin = 2.26% (Net Income TTM 6.29b / Revenue TTM 278b)
Gross Margin = 9.30% ((Revenue TTM 278b - Cost of Revenue TTM 252b) / Revenue TTM)
Gross Margin QoQ = 9.45% (prev 7.66%)
Tobins Q-Ratio = 0.65 (Enterprise Value 100b / Total Assets 153b)
Interest Expense / Debt = 4.44% (Interest Expense 1.38b / Debt 31.0b)
Taxrate = 18.02% (409.0m / 2.27b)
NOPAT = 7.64b (EBIT 9.32b * (1 - 18.02%))
Current Ratio = 0.82 (Total Current Assets 43.0b / Total Current Liabilities 52.6b)
Debt / Equity = 0.73 (Debt 31.0b / totalStockholderEquity, last quarter 42.2b)
Debt / EBITDA = 1.94 (Net Debt 23.1b / EBITDA 11.9b)
Debt / FCF = 3.02 (Net Debt 23.1b / FCF TTM 7.66b)
Total Stockholder Equity = 41.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.14% (Net Income 6.29b / Total Assets 153b)
RoE = 15.16% (Net Income TTM 6.29b / Total Stockholder Equity 41.5b)
RoCE = 13.16% (EBIT 9.32b / Capital Employed (Equity 41.5b + L.T.Debt 29.4b))
RoIC = 7.49% (NOPAT 7.64b / Invested Capital 102b)
WACC = 5.77% (E(77.1b)/V(108b) * Re(6.63%) + D(31.0b)/V(108b) * Rd(4.44%) * (1-Tc(0.18)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.89 | Cagr: -4.72%
[DCF] Terminal Value 77.97% ; FCFF base≈7.00b ; Y1≈8.02b ; Y5≈11.8b
[DCF] Fair Price = 584.4 (EV 178b - Net Debt 23.1b = Equity 155b / Shares 264.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.70 | EPS CAGR: 10.32% | SUE: 0.87 | # QB: 1
Revenue Correlation: 98.47 | Revenue CAGR: 17.78% | SUE: 1.48 | # QB: 13
EPS current Quarter (2026-06-30): EPS=7.56 | Chg30d=+2.27% | Revisions=+25% | Analysts=21
EPS next Quarter (2026-09-30): EPS=7.62 | Chg30d=-2.12% | Revisions=-42% | Analysts=21
EPS current Year (2026-12-31): EPS=30.40 | Chg30d=+0.19% | Revisions=+67% | GrowthEPS=+1.9% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=33.55 | Chg30d=+0.30% | Revisions=+39% | GrowthEPS=+10.3% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +67%